|
Long
Term Survival in a Patient with Recurrent Malignant Glioma Treated with
Intratumoral Infusion of an IL4-Targeted Toxin (NBI-3001)
N.G.
Rainov, V. Heidecke
Department
of Neurological Science, University of Liverpool; The Walton Centre for
Neurology and Neurosurgery NHS Trust, Liverpool, UK (N.G.R.); Department of
Neurosurgery, Martin-Luther University, Halle, Germany (V.H.)
Intratumoral
infusion of a recombinant targeted toxin (NBI-3001) consisting of the receptor
binding domain of human interleukin 4 (1L-4) and Pseudomonas aeruginosa
exotoxin A is an investigational treatment for malignant brain tumors.
This 27-year-old male patient presented with a recurrent malignant glioma WHO
grade IV after surgery and adjuvant radiation and chemotherapy.
The recurrence was treated with intratumoral infusion of NBI-3001 at a dose of 9
μg/ml
in 66 ml of infusate.
Treatment resulted in long-term survival for 3 years after toxin infusion with a
durable tumor response.
There were some permanent neurological side effects resulting from toxin
infusion.
The patient eventually died after a late local recurrence of the known brain
tumor.
Such
clinical evolution of a malignant glioma after a single round of immunotoxin
infusion is rather unusual.
The late local recurrence may suggest that repeated courses rather than a single
infusion of intratumoral toxin are possibly needed for successful long term
tumor control.
Keywords:
astrocytoma, glioblastoma, immunotoxin, interleukin-4 receptor, NBI-3001
Copyright
©
2004 Kluwer Academic Publishers.
All rights reserved
Source: http://www.kluweronline.com/article.asp?J=5042&I=108&A=12
|
